Does the LINX procedure achieve similar reflux control and improve postoperative symptoms, specifically gas bloating and inability to belch, when compared to laparoscopic fundoplication?

ISRCTN ISRCTN13533177
DOI https://doi.org/10.1186/ISRCTN13533177
IRAS number 331404
Secondary identifying numbers CPMS 58022, IRAS 331404
Submission date
28/05/2024
Registration date
03/06/2024
Last edited
03/06/2024
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
Reflux disease, where stomach acid leaks up into the oesophagus (food pipe), can severely impact quality of life and lead to complications, including ulceration of the oesophagus. It is often controlled with self-help measures and medication. However, sometimes surgery is recommended. The current standard surgical treatment is called a fundoplication. This operation is carried out through keyhole (laparoscopic) surgery and tightens the lower oesophagus to prevent reflux. Fundoplication is very safe and improves the quality of life of most patients. However, many patients have gas bloating, difficulty swallowing and recurrence of their reflux symptoms.
As an alternative, some surgeons use a device called LINX and a keyhole procedure. LINX is a magnetic device that wraps around the lower oesophagus to prevent reflux. Studies suggest that LINX may cause fewer complications with a similar improvement in quality of life. However, there is a need for better evidence to compare LINX with fundoplication in the surgical treatment of reflux disease.

Who can participate?
Patients aged 18 years and above with gastro-oesophageal reflux disease that is insufficiently controlled by medical treatment or intolerance to medical treatment being considered for anti-reflux surgery

What does the study involve?
Patients will be randomly allocated to undergo either a laparoscopic LINX procedure or fundoplication. All participants will be followed up at 6 weeks, 6, 12 and 24 months to assess which treatment offers the best results after surgery. Quality of life, surgical complications, including the need for additional treatment, financial cost-effectiveness and the presence of acid that has refluxed into the lower oesophagus are all measured. A quality assurance programme within participating centres will ensure that procedures are completed to a high-quality standard. Study results will incorporate a patient and public involvement programme, which will inform national and international guidelines for the surgical treatment of reflux disease.

What are the possible benefits and risks of participating?
The information from this study will help us understand whether the LINX procedure gives similar reflux control and improves symptoms after the operation, particularly gas bloating and not being able to burp, when compared to fundoplication at 24 months after surgery. At the moment this remains an unanswered question and this is why the researchers are doing this study.
Both fundoplication and the LINX procedure are well tolerated, but it is uncertain how common the side effects are with LINX compared to fundoplication - they could be similar, worse, or better; hence the need for this study to compare and find out. Both operations can result in gas bloating, difficulty belching and swallowing or an eventual recurrence of reflux symptoms after surgery and the need for reintervention or reoperation.

Where is the study run from?
University of Oxford (UK)

When is the study starting and how long is it expected to run for?
July 2023 to June 2028

Who is funding the study?
NIHR Efficacy and Mechanism Evaluation (EME) Programme (UK)

Who is the main contact?
GOLF Trial Manager, golf@nds.ox.ac.uk

Contact information

Prof Sheraz Markar
Principal Investigator

Surgical Intervention Trials Unit (SITU)
University of Oxford
Botnar Research Centre
Nuffield Orthopaedic Centre
Old Road
Headington
Oxford
OX3 7LD
United Kingdom

ORCiD logoORCID ID 0000-0001-8650-2017
Phone +44 (0) 7407 894087
Email sheraz.markar@nds.ox.ac.uk

Study information

Study designInterventional; Design type: Treatment, Device, Surgery
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleDouble-blind randomised controlled trial for treatment of Gastro-Oesophageal reflux disease; LINX management system vs Fundoplication (GOLF)
Study acronymGOLF
Study hypothesisThis study aims to determine whether the LINX procedure achieves similar reflux control and improves postoperative symptoms, specifically gas bloating and inability to belch when compared to fundoplication at 24 months after surgery.
Ethics approval(s)Approved 21/05/2024, Wales REC6 (Floor 4, Institute of Life Science 2, Swansea University, Swansea, SA2 8PP, UK; Wales.REC6@wales.nhs.uk), ref: 24/WA/0154
ConditionGastro-oesophageal reflux disease
InterventionThe GOLF study is a multi-centre, pragmatic, two-arm, double-blind, Phase III, randomized controlled trial (RCT). An embedded QuinteT Recruitment Intervention will be used to understand, monitor and address barriers to participation.

The study will recruit 460 patients (230 in each of two arms) recommended for anti-reflux surgery with gastro-oesophageal reflux disease (GORD) from at least 16 UK and 7 non-UK European large upper gastro-intestinal surgical centres. Patients will be randomized 1:1 to receive either a laparoscopic LINX procedure or fundoplication.

The primary outcome is the assessment of symptomatic GORD using the GORD-HRQL questionnaire at 24 months following surgery, and core secondary outcomes are the prevalence of inability to belch and gas bloating at 24 months also assessed by GORD-HRQL. Patients will be followed up either in clinic, via telephone or electronically at baseline, 6 weeks, 6, 12 and 24 months after surgery.
Intervention typeProcedure/Surgery
Primary outcome measureSymptomatic GORD and health-related quality of life (HRQL) assessed using the GORD-HRQL questionnaire at 24 months following surgery
Secondary outcome measures1. Prevalence of gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire at 24 months postoperatively
2. Prevalence of inability to belch measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire at 24 months postoperatively
3. Prevalence of symptomatic GORD, inability to belch and gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire at 6 weeks, 6 and 12 months after surgery
4. Severity of dysphagia and regurgitation measured using participant-reported outcomes/GORD-HRQL questionnaire at 6 weeks, 6, 12 and 24 months postoperatively
5. Global HRQL measured using participant-reported outcomes/EQ-5D-5L questionnaire at 6 weeks, 6, 12 and 24 months postoperatively
6. Utilisation of anti-GORD medications measured using participant-reported outcomes/questionnaire at 6 weeks, 6, 12 and 24 months postoperatively
7. 24-hour pH measurement measured using participant’s medical records/24-hour pH measurement or BRAVO test at 12 months postoperatively
8. 30-day, 90-day, 12 and 24-month postoperative complication rates, including reoperation and endoscopic reintervention, measured using participant’s medical records/postoperative outcomes
9. Cost-effectiveness of both treatments as measured by incremental cost per quality-adjusted life year (QALY) at 6 weeks, 6, 12 and 24 months postoperatively
Overall study start date01/07/2023
Overall study end date30/06/2028

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 460; UK Sample Size: 460
Participant inclusion criteria1. Age 18 years and above
2. Willing and able to give informed consent
3. Patients with GORD insufficiently controlled by medical therapy or intolerance to medical therapy being considered for anti-reflux surgery
4. Symptomatic and objectively defined GORD; endoscopy with appearances or biopsies consistent with reflux oesophagitis, or 24-hour pH study or BRAVO test of the oesophagus consistent with GORD
5. No hiatal hernia or hiatal hernia <5 cm in length
6. Adequate lower oesophageal motility as defined by preoperative oesophageal manometry study. Oesophageal manometry will show a mean contractile amplitude of >30 mmHg or DCI >450 mmHg-s-cm in 70% of swallows.
Participant exclusion criteria1. Unsuitable for surgical intervention due to medical conditions precluding general anaesthesia
2. Suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials
3. Previous anti-reflux or gastric surgery
4. Previous or planned neurosurgical intervention
5. Oesophageal manometry showing complete absence of lower oesophageal contractility
Recruitment start date30/06/2024
Recruitment end date30/06/2026

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

Manchester Royal Infirmary
Cobbett House
Oxford Road
Manchester
M13 9WL
United Kingdom
Southmead Hospital
Southmead Road
Westbury-on-trym
Bristol
BS10 5NB
United Kingdom
Queen Alexandra Hospital
Southwick Hill Road
Cosham
Portsmouth
PO6 3LY
United Kingdom
James Cook University Hospital
James Cook University Hospital
Marton Road
Middlesbrough
TS4 3BW
United Kingdom
The Whittington Hospital
Highgate Hill
London
N19 5NF
United Kingdom
Gloucestershire Royal Hospital
Great Western Road
Gloucester
GL1 3NN
United Kingdom
Heartlands Hospital
Bordesley Green East
Bordesley Green
Birmingham
B9 5ST
United Kingdom
St Marys Hospital
St. Marys Hospital
Floyd Drive
Warrington
WA2 8DB
United Kingdom
Southampton General Hospital
Southampton General Hospital
Tremona Road
Southampton
SO16 6YD
United Kingdom
North Devon District Hospital
Raleigh Park
Barnstaple
EX31 4JB
United Kingdom
St Thomas' Hospital
St. Thomas's Hospital
Westminster Bridge Road
London
SE1 7EH
United Kingdom
Darent Valley Hospital
Darenth Wood Road
Dartford
DA2 8DA
United Kingdom
Royal Derby Hospital
Uttoxeter Road
Derby
DE22 3NE
United Kingdom
Warwick Hospital
Lakin Road
Warwick
CV34 5BW
United Kingdom
Churchill Hospital
Churchill Hospital
Old Road
Headington
Oxford
OX3 7LE
United Kingdom
Royal Devon and Exeter Hospital
Royal Devon & Exeter Hospital
Barrack Road
Exeter
EX2 5DW
United Kingdom
Torbay Hospital
Torbay Hospital
Newton Road
Torquay
TQ2 7AA
United Kingdom
Epsom and St Helier University Hospitals
St. Helier Hospital
Wrythe Lane
Carshalton
SM5 1AA
United Kingdom
Nottingham University Hospital
Nottingham University Hospital
Derby Road
Nottingham
NG7 2UH
United Kingdom
Croydon University Hospital
London Road
Croydon
CR7 7YE
United Kingdom
Russells Hall Hospital
Pensnett Road
Dudley
DY1 2HQ
United Kingdom
The James Cook University Hospital
Marton Road
Middlesbrough
TS4 3BW
United Kingdom

Sponsor information

University of Oxford
University/education

Joint Research Office
Boundary Brook House
Churchill Drive
Headington
Oxford
OX3 7GB
England
United Kingdom

Email RGEA.Sponsor@admin.ox.ac.uk
Website http://www.ox.ac.uk/
ROR logo "ROR" https://ror.org/052gg0110

Funders

Funder type

Government

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR152268

No information available

Results and Publications

Intention to publish date30/06/2028
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal. Trial results will be available on the trial website.
IPD sharing planThe data-sharing plans for the current study are unknown and will be made available at a later date

Editorial Notes

28/05/2024: Study's existence confirmed by the NIHR.